Spectrum of HIV lymphoma 2009
Spectrum of HIV lymphoma 2009
复制标题
DOI：
10.1097/moh.0b013e328338f6b6
复制
发表时间：
2010-07-01
影响因子：
3.2
通讯作者：
Noy, Ariela
中科院分区：
文献类型：
--
作者：
Gucalp, Ayca;Noy, Ariela
综述的目的尽管使用了联合抗逆转录病毒治疗，但艾滋病毒感染者患恶性肿瘤的风险仍在增加。在发达国家影响艾滋病毒感染者的恶性肿瘤中，淋巴瘤占很大比例。本文综述了2009年至2010年1月发表的HIV淋巴瘤研究的最新进展。最近的发现该领域的研究主要集中在弥漫性大B细胞淋巴瘤，输注治疗仍然是有希望的。利妥昔单抗可能改善完全反应和可能的总存活率，但可能与CD4细胞计数非常低的一部分患者的感染增加有关。与淋巴瘤发展相关的危险因素包括CD4细胞计数低和可能的累积性HIV病毒血症。总体而言，随着对病理生理学和治疗的深入了解，HIV淋巴瘤的预后持续改善。
Purpose of reviewHIV-infected individuals remain at an increased risk for developing malignancies despite the use of combined antiretroviral therapy. Lymphomas comprise a large proportion of the malignancies that affect the HIV-infected population in developed countries. This review summarizes the recent progress made in HIV lymphoma research published in 2009 through January 2010.Recent findingsThe majority of investigation in this field has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising. Rituximab likely improves complete response and possibly overall survival, but may be associated with increased infections in a subset of patients with very low CD4 cell counts. Risk factors associated with the development of lymphoma include low CD4 cell count and likely cumulative HIV viremia. Biologic insights have been realized regarding pathogenesis.SummaryOverall, the outcome for HIV lymphoma continues to improve as insights into the pathophysiology and treatment advance.